MedTrace Logo

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

NCT04202835 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-05-11

No results posted yet for this study

Summary

A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.

Conditions

Interventions

DRUG

Cyclophosphamide

Post Transplant Cyclophosphamide

DRUG

Anti-Thymocyte globulin (rabbit)

Anti-Thymocyte Globulin (rabbit, Thymoglobulin)

Sponsors & Collaborators

  • Cell Therapy Transplant Canada

    collaborator UNKNOWN

  • Sanofi

    collaborator INDUSTRY

  • Ozmosis Research Inc.

    collaborator INDUSTRY

  • McMaster University

    lead OTHER

Principal Investigators

  • Irwin R Walker, MBBS · McMaster University

  • Kristjan Paulson, MD · CancerCare Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-14
Primary Completion
2024-05-18
Completion
2026-02-07
FDA Drug
Yes

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202835 on ClinicalTrials.gov